Click here to close Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly. We suggest using a current version of Chrome, FireFox, or Safari.

Summary Expression Phenotypes Gene Literature (71) GO Terms (6) Nucleotides (57) Proteins (36) Interactants (59) Wiki

Papers associated with p2rx1

Limit to papers also referencing gene:

Results 1 - 50 of 71 results

Page(s): 1 2 Next

Sort Newest To Oldest Sort Oldest To Newest

Tonic Calcium-Activated Chloride Current Sustained by ATP Release and Highly Desensitizing Human P2X1 Receptors., Limon A, Hagopian G, Reyes-Ruiz JM, Miledi R., Neuroscience. July 15, 2020; 439 332-341.

Identification of aurintricarboxylic acid as a potent allosteric antagonist of P2X1 and P2X3 receptors., Obrecht AS, Urban N, Schaefer M, Röse A, Kless A, Meents JE, Lampert A, Abdelrahman A, Müller CE, Schmalzing G, Hausmann R., Neuropharmacology. November 1, 2019; 158 107749.

A challenge finding P2X1 and P2X4 ligands., Beswick P, Wahab B, Honey MA, Paradowski M, Jiang K, Lochner M, Murrell-Lagnado RD, Thompson AJ., Neuropharmacology. October 1, 2019; 157 107674.

Comparative Embryonic Spatio-Temporal Expression Profile Map of the Xenopus P2X Receptor Family., Blanchard C, Boué-Grabot E, Massé K., Front Cell Neurosci. January 1, 2019; 13 340.                    

Mapping the binding site of the P2X receptor antagonist PPADS reveals the importance of orthosteric site charge and the cysteine-rich head region., Huo H, Fryatt AG, Farmer LK, Schmid R, Evans RJ., J Biol Chem. August 17, 2018; 293 (33): 12820-12831.                

Two P2X1 receptor transcripts able to form functional channels are present in most human monocytes., López-López C, Jaramillo-Polanco J, Portales-Pérez DP, Gómez-Coronado KS, Rodríguez-Meléndez JG, Cortés-García JD, Espinosa-Luna R, Montaño LM, Barajas-López C., Eur J Pharmacol. December 15, 2016; 793 82-88.

Mechanistic insights from resolving ligand-dependent kinetics of conformational changes at ATP-gated P2X1R ion channels., Fryatt AG, Dayl S, Cullis PM, Schmid R, Evans RJ., Sci Rep. September 12, 2016; 6 32918.              

Presynaptic P2X1-3 and α3-containing nicotinic receptors assemble into functionally interacting ion channels in the rat hippocampus., Rodrigues RJ, Almeida T, Díaz-Hernández M, Marques JM, Franco R, Solsona C, Miras-Portugal MT, Ciruela F, Cunha RA., Neuropharmacology. June 1, 2016; 105 241-257.

Contribution of the Juxtatransmembrane Intracellular Regions to the Time Course and Permeation of ATP-gated P2X7 Receptor Ion Channels., Allsopp RC, Evans RJ., J Biol Chem. June 5, 2015; 290 (23): 14556-66.                

Use of chimeras, point mutants, and molecular modeling to map the antagonist-binding site of 4,4',4″,4‴-(carbonylbis-(imino-5,1,3-benzenetriylbis(carbonylimino)))tetrakisbenzene-1,3-disulfonic acid (NF449) at P2X1 receptors for ATP., Farmer LK, Schmid R, Evans RJ., J Biol Chem. January 16, 2015; 290 (3): 1559-69.              

Validation of Alexa-647-ATP as a powerful tool to study P2X receptor ligand binding and desensitization., Bhargava Y, Nicke A, Rettinger J., Biochem Biophys Res Commun. August 23, 2013; 438 (2): 295-300.

P2X receptor chimeras highlight roles of the amino terminus to partial agonist efficacy, the carboxyl terminus to recovery from desensitization, and independent regulation of channel transitions., Allsopp RC, Farmer LK, Fryatt AG, Evans RJ., J Biol Chem. July 19, 2013; 288 (29): 21412-21421.                

Gintonin, a ginseng-derived lysophosphatidic acid receptor ligand, potentiates ATP-gated P2X₁ receptor channel currents., Choi SH, Kim HJ, Kim BR, Shin TJ, Hwang SH, Lee BH, Lee SM, Rhim H, Nah SY., Mol Cells. February 1, 2013; 35 (2): 142-50.

Mass spectrometry analysis of human P2X1 receptors; insight into phosphorylation, modelling and conformational changes., Roberts JA, Bottrill AR, Mistry S, Evans RJ., J Neurochem. December 1, 2012; 123 (5): 725-35.          

Involvement of the cysteine-rich head domain in activation and desensitization of the P2X1 receptor., Lörinczi É, Bhargava Y, Marino SF, Taly A, Kaczmarek-Hájek K, Barrantes-Freer A, Dutertre S, Grutter T, Rettinger J, Nicke A., Proc Natl Acad Sci U S A. July 10, 2012; 109 (28): 11396-401.

P2X2 and P2X5 subunits define a new heteromeric receptor with P2X7-like properties., Compan V, Ulmann L, Stelmashenko O, Chemin J, Chaumont S, Rassendren F., J Neurosci. March 21, 2012; 32 (12): 4284-96.

Agonist binding evokes extensive conformational changes in the extracellular domain of the ATP-gated human P2X1 receptor ion channel., Roberts JA, Allsopp RC, El Ajouz S, Vial C, Schmid R, Young MT, Evans RJ., Proc Natl Acad Sci U S A. March 20, 2012; 109 (12): 4663-7.

Molecular basis of selective antagonism of the P2X1 receptor for ATP by NF449 and suramin: contribution of basic amino acids in the cysteine-rich loop., El-Ajouz S, Ray D, Allsopp RC, Evans RJ., Br J Pharmacol. January 1, 2012; 165 (2): 390-400.          

Cloning and functional analysis of P2X1b, a new variant in rat optic nerve that regulates the P2X1 receptor in a use-dependent manner., Rangel-Yescas GE, Vazquez-Cuevas FG, Garay E, Arellano RO., Acta Neurobiol Exp (Wars). January 1, 2012; 72 (1): 18-32.

Cloning and characterization of a P2X receptor expressed in the central nervous system of Lymnaea stagnalis., Bavan S, Straub VA, Webb TE, Ennion SJ., PLoS One. January 1, 2012; 7 (11): e50487.                

The intracellular amino terminus plays a dominant role in desensitization of ATP-gated P2X receptor ion channels., Allsopp RC, Evans RJ., J Biol Chem. December 30, 2011; 286 (52): 44691-701.            

Cysteine scanning mutagenesis (residues Glu52-Gly96) of the human P2X1 receptor for ATP: mapping agonist binding and channel gating., Allsopp RC, El Ajouz S, Schmid R, Evans RJ., J Biol Chem. August 19, 2011; 286 (33): 29207-17.              

Contribution of the intracellular C terminal domain to regulation of human P2X1 receptors for ATP by phorbol ester and Gq coupled mGlu(1α) receptors., Wen H, Evans RJ., Eur J Pharmacol. March 5, 2011; 654 (2): 155-9.        

Discovery of potent competitive antagonists and positive modulators of the P2X2 receptor., Baqi Y, Hausmann R, Rosefort C, Rettinger J, Schmalzing G, Müller CE., J Med Chem. February 10, 2011; 54 (3): 817-30.

Amino acid residues constituting the agonist binding site of the human P2X3 receptor., Bodnar M, Wang H, Riedel T, Hintze S, Kato E, Fallah G, Gröger-Arndt H, Giniatullin R, Grohmann M, Hausmann R, Schmalzing G, Illes P, Rubini P., J Biol Chem. January 28, 2011; 286 (4): 2739-49.

Selective potentiation of homomeric P2X2 ionotropic ATP receptors by a fast non-genomic action of progesterone., De Roo M, Boué-Grabot E, Schlichter R., Neuropharmacology. March 1, 2010; 58 (3): 569-77.

Contribution of the region Glu181 to Val200 of the extracellular loop of the human P2X1 receptor to agonist binding and gating revealed using cysteine scanning mutagenesis., Roberts JA, Valente M, Allsopp RC, Watt D, Evans RJ., J Neurochem. May 1, 2009; 109 (4): 1042-52.              

A P2X receptor from the tardigrade species Hypsibius dujardini with fast kinetics and sensitivity to zinc and copper., Bavan S, Straub VA, Blaxter ML, Ennion SJ., BMC Evol Biol. January 20, 2009; 9 17.            

Regions of the amino terminus of the P2X receptor required for modification by phorbol ester and mGluR1alpha receptors., Wen H, Evans RJ., J Neurochem. January 1, 2009; 108 (2): 331-40.            

Direct modulation of P2X1 receptor-channels by the lipid phosphatidylinositol 4,5-bisphosphate., Bernier LP, Ase AR, Tong X, Hamel E, Blais D, Zhao Q, Logothetis DE, Séguéla P., Mol Pharmacol. September 1, 2008; 74 (3): 785-92.

Cysteine substitution mutagenesis and the effects of methanethiosulfonate reagents at P2X2 and P2X4 receptors support a core common mode of ATP action at P2X receptors., Roberts JA, Digby HR, Kara M, El Ajouz S, Sutcliffe MJ, Evans RJ., J Biol Chem. July 18, 2008; 283 (29): 20126-36.                

Lack of evidence for direct phosphorylation of recombinantly expressed P2X(2) and P2X (3) receptors by protein kinase C., Franklin C, Braam U, Eisele T, Schmalzing G, Hausmann R., Purinergic Signal. September 1, 2007; 3 (4): 377-88.              

Cysteine substitution mutants give structural insight and identify ATP binding and activation sites at P2X receptors., Roberts JA, Evans RJ., J Neurosci. April 11, 2007; 27 (15): 4072-82.

Identification of an intersubunit cross-link between substituted cysteine residues located in the putative ATP binding site of the P2X1 receptor., Marquez-Klaka B, Rettinger J, Bhargava Y, Eisele T, Nicke A., J Neurosci. February 7, 2007; 27 (6): 1456-66.

Contribution of P2X1 receptor intracellular basic residues to channel properties., Vial C, Rigby R, Evans RJ., Biochem Biophys Res Commun. November 10, 2006; 350 (1): 244-8.

Contribution of conserved polar glutamine, asparagine and threonine residues and glycosylation to agonist action at human P2X1 receptors for ATP., Roberts JA, Evans RJ., J Neurochem. February 1, 2006; 96 (3): 843-52.

Contribution of conserved glycine residues to ATP action at human P2X1 receptors: mutagenesis indicates that the glycine at position 250 is important for channel function., Digby HR, Roberts JA, Sutcliffe MJ, Evans RJ., J Neurochem. December 1, 2005; 95 (6): 1746-54.

Potentiation of P2X1 ATP-gated currents by 5-hydroxytryptamine 2A receptors involves diacylglycerol-dependent kinases and intracellular calcium., Ase AR, Raouf R, Bélanger D, Hamel E, Séguéla P., J Pharmacol Exp Ther. October 1, 2005; 315 (1): 144-54.

Regulatory interdependence of cloned epithelial Na+ channels and P2X receptors., Wildman SS, Marks J, Churchill LJ, Peppiatt CM, Chraibi A, Shirley DG, Horisberger JD, King BF, Unwin RJ., J Am Soc Nephrol. September 1, 2005; 16 (9): 2586-97.

Inhibition of platelet functions and thrombosis through selective or nonselective inhibition of the platelet P2 receptors with increasing doses of NF449 [4,4',4'',4'''-(carbonylbis(imino-5,1,3-benzenetriylbis-(carbonylimino)))tetrakis-benzene-1,3-disulfonic acid octasodium salt]., Hechler B, Magnenat S, Zighetti ML, Kassack MU, Ullmann H, Cazenave JP, Evans R, Cattaneo M, Gachet C., J Pharmacol Exp Ther. July 1, 2005; 314 (1): 232-43.

Profiling at recombinant homomeric and heteromeric rat P2X receptors identifies the suramin analogue NF449 as a highly potent P2X1 receptor antagonist., Rettinger J, Braun K, Hochmann H, Kassack MU, Ullmann H, Nickel P, Schmalzing G, Lambrecht G., Neuropharmacology. March 1, 2005; 48 (3): 461-8.

Mutagenesis studies of conserved proline residues of human P2X receptors for ATP indicate that proline 272 contributes to channel function., Roberts JA, Evans RJ., J Neurochem. March 1, 2005; 92 (5): 1256-64.

Biochemical and functional evidence for heteromeric assembly of P2X1 and P2X4 subunits., Nicke A, Kerschensteiner D, Soto F., J Neurochem. February 1, 2005; 92 (4): 925-33.

Trimeric architecture of homomeric P2X2 and heteromeric P2X1+2 receptor subtypes., Aschrafi A, Sadtler S, Niculescu C, Rettinger J, Schmalzing G., J Mol Biol. September 3, 2004; 342 (1): 333-43.

G-protein-coupled receptor regulation of P2X1 receptors does not involve direct channel phosphorylation., Vial C, Tobin AB, Evans RJ., Biochem J. August 15, 2004; 382 (Pt 1): 101-10.

ATP binding at human P2X1 receptors. Contribution of aromatic and basic amino acids revealed using mutagenesis and partial agonists., Roberts JA, Evans RJ., J Biol Chem. March 5, 2004; 279 (10): 9043-55.

Desensitization masks nanomolar potency of ATP for the P2X1 receptor., Rettinger J, Schmalzing G., J Biol Chem. February 20, 2004; 279 (8): 6426-33.

Dissecting individual current components of co-expressed human P2X1 and P2X7 receptors., Seyffert C, Schmalzing G, Markwardt F., Curr Top Med Chem. January 1, 2004; 4 (16): 1719-30.

NF449, a novel picomolar potency antagonist at human P2X1 receptors., Hülsmann M, Nickel P, Kassack M, Schmalzing G, Lambrecht G, Markwardt F., Eur J Pharmacol. May 30, 2003; 470 (1-2): 1-7.

Activation and desensitization of the recombinant P2X1 receptor at nanomolar ATP concentrations., Rettinger J, Schmalzing G., J Gen Physiol. May 1, 2003; 121 (5): 451-61.          

Page(s): 1 2 Next